|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Dental and Craniofacial Research (NIDCR) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001344 |
Purpose
In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by sensitization of central nervous system neurons caused by excitatory amino acid neurotransmitters, acting largely through NMDA receptors. A previous small trial of dextromethorphan suggested efficacy in diabetic neuropathy pain. The study requires one visit to the NIH outpatient Pain Research Clinic, and consists of three 9-week treatment periods. Patients who respond to one of the medications will be invited to participate in further controlled studies of the medication followed by up to several years of open-label treatment under continued observation.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Neuropathies Herpes Zoster Neuralgia |
Drug: dextromethorphan |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Safety/Efficacy Study |
| Official Title: | Dextromethorphan Versus Placebo for Neuropathic Pain |
| Estimated Enrollment: | 129 |
| Study Start Date: | March 1993 |
| Estimated Study Completion Date: | February 2001 |
In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by sensitization of central nervous system neurons caused by excitatory amino acid neurotransmitters, acting largely through NMDA receptors. A previous small trial of dextromethorphan suggested efficacy in diabetic neuropathy pain. The study requires one visit to the NIH outpatient Pain Research Clinic, and consists of three 9-week treatment periods. Patients who respond to one of the medications will be invited to participate in further controlled studies of the medication followed by up to several years of open-label treatment under continued observation.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients must be over 18 years of age.
Patients must have a definite diagnosis of diabetic neuropathy or post herpetic neuralgia or a diagnosis of neuropathic pain of various etiologies other than diabetic neuropathy or post herpetic neuralgia.
Duration of symptoms must be at least 3 months.
Severity of pain must be at least mild, if constant; or at least moderate, if intermittent and at least 2 hours duration a day.
Patients using tricyclics, narcotics, or antiseizure medications, must keep the drug dosages constant throughout the study.
No patients with unstable disease process; i.e., angina pectoris, accelerated hypertension, recent stroke or transient cerebral ischemia, uncontrolled seizures.
No pregnant or lactating women. Women of child bearing potential must use birth control pills, intrauterine device, or barrier contraceptive devices.
No history of significant drug abuse or PCP use. No history of IV drug abuse, prescription drug abuse, or alcoholism.
No significant liver or kidney disease.
No MAO inhibitors.
No cognitive impairment or language difficulty as judged by difficulty completing pain diary, medical history, or telephone conversation.
Patients must not have any other chronic pain condition that gives them pain greater than the neuropathy pain.
Contacts and Locations More Information
| Study ID Numbers: | 930114, 93-D-0114 |
| Study First Received: | November 3, 1999 |
| Last Updated: | March 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001344 |
| Health Authority: | United States: Federal Government |
|
Diabetes Mellitus Diabetic Neuropathy Memantine NMDA Receptor Antagonists |
Neuropathic Pain Neuropathy Post-Herpetic Neuralgia Shingles |
|
Herpes Zoster Neuralgia, Postherpetic Excitatory Amino Acids Diabetic Neuropathies Neuralgia Diabetes Mellitus Endocrine System Diseases Pain Herpesviridae Infections Naphazoline Virus Diseases Oxymetazoline |
Signs and Symptoms Neuromuscular Diseases Guaifenesin Phenylephrine Peripheral Nervous System Diseases Dextromethorphan Memantine Neurologic Manifestations DNA Virus Infections Phenylpropanolamine Endocrinopathy Diabetes Complications |
|
Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Excitatory Amino Acid Agents Antitussive Agents Central Nervous System Agents Pharmacologic Actions Excitatory Amino Acid Antagonists |
